What is MannKind's (MannKind) stock price potential in the next year?
6 brokerages have issued 1 year target prices for MannKind's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's stock price to reach $6.30 in the next year. This suggests a possible upside of 66.2% from the stock's current price.
Who are the insiders of MannKind?
Company insiders that own MannKind stock include Alejandro Galindo, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends for MannKind. Which institutional investors are selling MannKind stock?
What does the company MannKind do?
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.
What did Michael Castagna say about today’s news hammering mnkd stock?
Michael Castagna, PharmD, CEO of MannKind, said the following about today’s news hammering MNKD stock. “We continue to build pre-launch inventory of Tyvaso DPI and look forward to supporting United Therapeutics’ efforts in securing approval of Tyvaso DPI in the coming months.”
See more
Should I buy or sell MannKind stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy rat...
What is MannKind's stock price forecast for 2022?
3 brokers have issued twelve-month target prices for MannKind's shares. Their forecasts range from $6.00 to $6.00. On average, they predict MannKin...
How has MannKind's stock performed in 2022?
MannKind's stock was trading at $4.37 at the beginning of 2022. Since then, MNKD shares have decreased by 0.5% and is now trading at $4.35. View t...
When is MannKind's next earnings date?
MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for MannKind .
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) released its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share f...
Who are MannKind's key executives?
MannKind's management team includes the following people: Dr. Michael E. Castagna Pharm.D. , CEO & Director (Age 45, Pay $1.12M) Mr. Steven B. B...
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceu...
What other stocks do shareholders of MannKind own?
Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BH...
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How Much Of MannKind Corporation (NASDAQ:MNKD) Do Institutions Own?
When will Mannkind close?
The big shareholder groups in MannKind Corporation ( NASDAQ:MNKD ) have power over the company . Insiders often own a...
What is the ticker symbol for Mannkind?
09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8 , 2021, of its previously announced sale-leaseback transaction with an affiliate of Creative Manufacturing Properties. The transaction results in $102.25 million in non-dilutive gross proceeds to MannKind
What is Mannkind's official website?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How much money does MannKind make?
The official website for MannKind is www.mannkindcorp.com.
Where are MannKind's headquarters?
MannKind has a market capitalization of $959.80 million and generates $65.14 million in revenue each year. The biopharmaceutical company earns $-57.24 million in net income (profit) each year or ($0.32) on an earnings per share basis.
What is MarketBeat ratings?
MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.
Where is Mannkind located?
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote “Outperform” if you believe MNKD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is Mannkind's P/E ratio?
It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
What is the dividend payout ratio of ManpowerGroup?
The P/E ratio of MannKind is -14.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is MarketBeat community ratings?
ManpowerGroup does not yet have a strong track record of dividend growth. The dividend payout ratio of ManpowerGroup is 68.66%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ManpowerGroup will have a dividend payout ratio of 29.72% next year.
What is the P/E ratio of ManpowerGroup?
MarketBeat's community ratings are surveys of what our community members think about ManpowerGroup and other stocks. Vote “Outperform” if you believe MAN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Component Grades
The P/E ratio of ManpowerGroup is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.58.
MAN POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
MAN Stock Summary
MAN scores best on the Value dimension, with a Value rank ahead of 96.57% of US stocks.
MAN Valuation Summary
The capital turnover (annual revenue relative to shareholder's equity) for MAN is 8.25 -- better than 96.39% of US stocks.
MAN's Quality Factors
In comparison to the median Industrials stock, MAN's price/sales ratio is 83.33% lower, now standing at 0.3.
Latest MAN News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching MAN
Below are the latest news stories about ManpowerGroup Inc that investors may wish to consider to help them evaluate MAN as an investment opportunity.
What is Man Industries?
Want to do more research on ManpowerGroup Inc's stock and its price? Try the links below:
What is face value of stock?
Man Industries (India) Ltd., incorporated in the year 1988, is a Small Cap company (having a market cap of Rs 569.60 Crore) operating in Metals - Ferrous sector. Man Industries (India) Ltd. key Products/Revenue Segments include Stainless Steel Tubes & Pipes, Other Operating Revenue and Sale of services for the year ending 31-Mar-2020.
What is the ranking of a company within its sector based on?
Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value.
What is TTM in stock?
This is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned.
What is dividend yield?
Earnings per share (TTM) tells the profit after tax earned on a per share basis by a stock over the last twelve months or four quarters.
